These trials are designed to further investigate the long-term safety, efficacy, and side effect profiles of retatrutide in diverse populations, including individuals with obesity, those overweight, with type 2 diabetes, obstructive sleep apnea, or osteoarthritis
None of these molecules is universally "better": the answer depends strictly on the research axis and the scientific question posed
Developed by Eli Lilly, retatrutide simultaneously targets GLP-1, GIP, and glucagon receptors, setting it apart from existing licensed treatments such as semaglutide and tirzepatide
Round up for priming losses, dropped syringes, damaged swabs, and any protocol adjustments
a , Representative image of hM3Dq expression in the DVC (AP and NTS)
Bottom Line + Next Step Choosing between tirzepatide and semaglutide depends on clinical priorities